CDKN2B Loss Reference Standard
CBP40055
詢 價
索取COA
產品描述
產品數(shù)據(jù)庫
| Introduction | ||
| Format | Genomic DNA | |
| Description | CDKN2B, cyclin dependent kinase inhibitor 2B, regulates G1-S phase cell cycle arrest via specific inhibition of CDK4 and CDK6 kinases to function as a tumor suppressor (PMID: 27030077). CDKN2B deletion and/or promoter hypermethylation is commonly observed in acute lymphoblastic leukemia (PMID: 30635552, PMID: 30592434) and CDKN2B deletions have also been reported in liposarcoma (PMID: 21910158), renal cell carcinoma (PMID: 23898052), and glioma (PMID: 30558563). | |
| Technical Data | ||
| Copy number | 0 | |
| Definition | Loss | |
| Product Information | ||
| Intended Use | Research Use Only | |
| Unit Size | 1ug | |
| Concentration | Download for COA | |
| Purity | Download for COA | |
| DNA electrophoresis | Download for COA | |
| Sanger sequencing | Download for COA | |
| Storage | 2-8℃ | |
| Expiry | 36 months from the date of manufacture | |
